Actinium Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Actinium Pharmaceuticals, Inc. (ATNM) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2018
Operating Activities
Net Income-38.24-48.82-33.02-24.77-22.22-23.65
Depreciation & Amortization0.810.790.700.520.450.05
Stock Based Compensation5.293.842.801.691.250.00
Change in Working Capital-0.93-3.1538.171.69-1.101.23
Change in Accounts Payable-0.39-2.184.601.20-0.260.00
Change in Other Working Capital-0.55-0.97-0.43-0.50-0.850.00
Other Operating Activities0.002.820.000.000.000.00
Net Cash from Operating Activities-33.07-47.348.64-20.87-21.62-20.57
Investing Activities
Capital Expenditures-0.01-0.15-0.37-0.13-0.25-0.10
Net Cash from Investing Activities-0.01-0.15-0.37-0.13-0.25-0.10
Financing Activities
Debt Repayment-0.010.00-0.05-0.09-0.460.00
Common Stock Issued29.3314.6123.1635.3076.6416.98
Other Financing Activities0.080.000.000.000.000.00
Net Cash from Financing Activities29.3214.8723.1135.2276.1816.98
Summary
Net Change in Cash-3.76-32.6231.3914.2254.31-3.69
Cash at Beginning of Period76.99109.6178.2264.000.0017.79
Cash at End of Period73.2376.99109.6178.220.0014.10
Free Cash Flow-33.08-47.498.28-21.00-21.87-20.67
Supplemental Disclosures
Interest Paid0.000.000.000.000.010.00